News and Trends 19 Feb 2018 This Belgian Biotech Gives Us an Update on its Bulging Psoriasis Pipeline UCB has presented positive Phase IIb results for its psoriasis drug, bimekizumab, and outlined the Phase III testing of Cimzia for the condition at the American Academy of Dermatology’s annual meeting. Belgian biopharma, UCB, develops medicines for people suffering from severe diseases of the immune or central nervous systems. The company is developing a number […] February 19, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 19 Feb 2018 Taking CAR-T Cells Beyond Cancer: A New Therapy for Autoimmune Disease CAR-T cells are all the rage as the latest treatment for cancer. But what if we could apply this same technology to treat autoimmune disease? Curious to learn whether this new technology could revolutionize yet another field of medicine, I talked to Stephane Boissel, CEO of TxCell, to discuss the future of the field and his […] February 19, 2018 - 9 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jan 2018 Your Pee Could Be Used to Build an Artificial Adrenal Gland Scientists have started generating artificial glands using cells derived from urine, which will allow the study of adrenal disorders that affect growth, development, and metabolism. Researchers at Queen Mary University of London have used cells in urine to begin generating an artificial adrenal gland that could be used to treat adrenal gland disorders. The study, published in Cell Reports, […] January 31, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jan 2018 This Cytokine is Key to Autoimmune and Inflammatory Diseases An international group of researchers has found that the cytokine IL-23 is heavily involved in autoimmune and inflammatory diseases, opening the door to new therapies targeting the molecule. Research at the VIB-UGent Center for Inflammation Research has identified a crucial molecular mechanism underlying autoimmune and inflammatory diseases like psoriasis, rheumatoid arthritis, and multiple sclerosis. The study, […] January 18, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 11 Dec 2017 Belgian Antibody Proves Effective to Treat Myasthenia Gravis A Phase II proof of concept study has shown that one of Argenx’ antibodies is effective in treating the neuromuscular disease myasthenia gravis. Argenx has released the results from a Phase II trial with ARGX-113 (efgartigimod), in which the antibody therapy has proved to provide a significant improvement in patients with generalized myasthenia gravis, a form of the disease […] December 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2017 German Biotech Reels in €34M for its Cancer-Killing Technology Heidelberg Pharma is developing Antibody Targeted Amanitin Conjugates (ATACs), which combine antibody-drug conjugate technology with the toxin, Amanitin. Heidelberg Pharma has attracted over €34M of investment to support the development of its Antibody Targeted Amanitin Conjugates (ATACs) technology. The biotech, formerly Wilex, is developing drugs for cancer and autoimmune diseases, with the hope that the addition of Amanitin to antibody-drug conjugate (ADC) technology could produce […] November 21, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2017 French Biotech Steps Up Autoimmune Disease Drug Development with €14.5M Series A Step Pharma will use the proceeds of its first fundraising round to support the development of immunomodulators for autoimmune diseases towards the clinic. Step Pharma develops inhibitors targeting an enzyme called cytidine nucleotide triphosphate (CTPS1) for the treatment of a range of autoimmune diseases. The company is working on several candidates, the most advanced of which […] November 21, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2017 Update: Belgian Biotech Starts Human Trials for a Potential Type 1 Diabetes Cure Update (15/11/2017): Imcyse has officially started recruiting patients to test its therapy for type 1 diabetes. The clinical trial will recruit up to 40 patients across 15 European centers, and the first patient has already enrolled at the Steno Diabetes Center in Copenhagen. Originally published on 30/05/2017 Imcyse will run its first clinical trial testing […] November 15, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2017 German Biotech Pockets €18M in its Series A to Propel Autoimmune Disease Candidate Forward Topas Therapeutics received an extra €4M from Boehringer Ingelheim Venture Fund to help its autoimmune disease candidates accelerated through trials. Hamburg-based Topas Therapeutics, a spin-off from Evotec, develops products for autoimmune diseases with high medical need. With the announcement of a €18M Series A, it hopes to take begin moving its candidates into the clinic. It had raised €14M thanks to investment from Epidarex […] November 2, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2017 Belgian Biotech Launches IPO, Readying Itself to Fight Multiple Sclerosis Apitope develops highly specific peptide therapeutics for multiple sclerosis and other autoimmune diseases, and will now launch an IPO on Brussels Euronext. Apitope hopes to treat a number of autoimmune diseases affecting many systems throughout the body. The company has developed peptides, ‘apitopes‘, that tackle the immunological basis of the disease. The company has just […] November 1, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 28 Sep 2017 What are Alphabodies and How Do They Drug the Undruggable? Philip found out more about a new form of protein therapeutics being developed by Complix, which aims to drug the undruggable. Mark Vaeck, Co-Founder and CEO of Complix, has over 25 years experience in the biotech and pharma industries. His latest company Complix, a Belgian immuno-oncology biotech, is developing Alphabodies, tiny therapeutic proteins that can […] September 28, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 15 Sep 2017 Swiss-US Partners Reveal New Candidate for Autoimmune Disease Numab and Intarcia have a first candidate to combine a tri-specific antibody fragment with a mini-osmotic pump delivery system to fight autoimmune disease. Numab and Intarcia partnered in 2015 to develop a new form of treatment for diabetes, obesity and autoimmune diseases. After initial research, the team has now selected its first candidate for clinical […] September 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email